Cure & Advancements/January 28, 2025/2 min read

New Immunotherapies Show Promise in Slowing Type 1 Diabetes Progression

Researchers are developing treatments that target the immune system to delay or modify how Type 1 diabetes develops. These emerging approaches offer hope for people at risk or newly diagnosed.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Immunotherapies aim to slow the autoimmune attack on insulin-producing cells rather than replacing insulin
These treatments work by modifying immune system function, not by curing Type 1 diabetes
Research is ongoing to determine which patients benefit most and how to combine these therapies effectively
Disease modification could help preserve remaining insulin production and improve long-term health outcomes

Understanding Disease Modification

Type 1 diabetes occurs when the immune system mistakenly attacks the beta cells in the pancreas that produce insulin. Rather than simply replacing lost insulin, researchers are exploring ways to stop or slow this autoimmune attack—an approach called disease modification.

Disease-modifying treatments aim to preserve the body's remaining ability to produce insulin, even in small amounts. This differs from insulin therapy, which manages blood sugar but does not address the underlying immune problem.

How Immunotherapies Work

Emerging immunotherapies target specific parts of the immune system to reduce harmful autoimmune activity. These treatments work on the principle that controlling immune function early in the disease process may slow or delay the loss of insulin-producing cells.

Different approaches are being studied, each designed to re-educate or suppress the immune cells that attack the pancreas. The goal is to restore balance so the immune system stops harming insulin-producing cells.

Current Research and Development

Scientists are testing multiple immunotherapy candidates in clinical research settings. These studies help determine safety, effectiveness, and which populations of patients respond best to each treatment.

Researchers are also exploring how different immunotherapies might work together to provide better protection of insulin production. Combination approaches may offer more complete disease modification than single treatments alone.

What This Means for Patients and Families

Disease-modifying immunotherapies represent a shift toward earlier intervention in Type 1 diabetes. If effective, these treatments could help people diagnosed with Type 1 diabetes preserve more of their natural insulin production over time.

While immunotherapies show promise, they are still being developed and tested. Anyone interested in participating in clinical research should speak with their healthcare provider about available trials and eligibility.

Evidence label

Origin: springermedicine.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.